Evidence map›Paper›PMID 35360509›Full record

ArticleAdvances in radiation oncology

Worsening Racial Disparities in Utilization of Intensity Modulated Radiation Therapy.

Ryan J Hutten, Chris R Weil, David K Gaffney, Kristine Kokeny, Shane Lloyd, Charles R Rogers, Gita Suneja

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Disparities in Gynecologic Cancers.Cancer journal (Sudbury, Mass.)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ryan J HuttenDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
Chris R WeilDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
David K GaffneyDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
Kristine KokenyDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
Shane LloydDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
Charles R RogersDepartment of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Gita SunejaDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
University of Utah · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site ApplicationUG1CA233178 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Matthew Poppe, Heloisa Prado Soares · 2019 to 2026
$4.9M
Cancer Treatment Disparities in the HIV Population: Exploring the Impact of HIV on Physician and Patient Decision-MakingK08CA228631 · NCI · UNIVERSITY OF UTAH · PI SUNEJA, GITA · 2018 to 2022
$1.2M
Developing a Barbershop-Based Trial on Masculinity Barriers to Care and Colorectal Cancer Screening Uptake among African-American Men using a MixedMethods ApproachK01CA234319 · NCI · UNIVERSITY OF UTAH · PI ROGERS, CHARLES R. · 2018 to 2022
$878k
NCI NIH HHS K01 CA234319NCI NIH HHS K08 CA228631NCI NIH HHS P30 CA042014NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA233178
6 · The paper itself

Abstract

Purpose: The benefits of intensity modulated radiation therapy (IMRT) compared with standard 3-dimensional conformal radiation therapy have been demonstrated in many cancer sites and include decreased acute and late toxicity, improved quality of life, and opportunities for dose escalation. Limited literature suggests non-white patients may have lower utilization of IMRT. We hypothesized that as the use of IMRT has increased in recent years, racial inequities have persisted and disproportionately affect non-Hispanic Black (NHB) patients. We aim to evaluate temporal trends in IMRT utilization focusing on disparities among minoritized populations. Methods and Materials: The National Cancer Database was queried to identify the 10 disease sites with the highest total number of cancer patients treated with definitive intent IMRT in 2017, the most recent year for which data are available. Exclusions included stage IV, age <18 years, unknown insurance status, unknown race, and palliative intent radiation. Race and ethnicity variables were combined and classified as non-Hispanic White, Hispanic, NHB, Asian, Native American/Eskimo, and Hawaiian/Pacific Islander. Multivariable logistic regression for IMRT utilization was performed for each disease site for both early (2004-2010) and contemporary (2011-2017) cohorts, adjusting for clinical and demographic covariates. Results: Among the 10 selected disease sites, 1,010,292 patients received radiation therapy as part of definitive treatment between 2004 and 2017. Overall IMRT utilization rates increased from 22.0% in 2004 to 57.8% in 2017. After adjustment and compared with non-Hispanic White patients, NHB patients were significantly less likely to receive IMRT in 1 of 10 disease sites in the 2004 to 2010 cohort, and 5 of 10 disease sites in the 2011 to 2017 cohort. Conclusions: Despite greater awareness of racial disparities in cancer care and outcomes, this study demonstrates worsening disparities in the use of IMRT, particularly for NHB patients. These differences may exacerbate racial disparities in cancer outcomes; therefore, identification of underlying drivers of differential IMRT utilization is warranted.

Identifiers

PMID35360509
PMCPMC8960883
OpenAlexW4206447535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.